Opens in a new tab
Lean Seal ISO website iv removebg
ALWAYS AUDIT READY
Feasibility Inquiry

Accelerate Your Phase 1/2 Study Expansion

1st best choice for P1 2 study expansion
Share

Canada is a prime location for Phase 1/2 oncology clinical trial expansion. As agility becomes a key driver of global clinical success, Canadian oncology research centres—including dedicated Phase 1 units—stand out for their speed, flexibility, and readiness to support early-phase programs.

These centres are located in major population hubs and have developed streamlined activation processes for both dose-escalation and expansion cohorts. Led by leading oncologists and hematologists, their specialized teams are designed for rapid, high-quality execution.

When paired with a niche oncology CRO partner like Scimega—bringing deep regional expertise and long-standing site relationships—sponsors gain a powerful advantage to accelerate their Phase 1/2 expansion programs in Canada.

Canada Offers a Competitive Advantage for Phase 1/2 Cohort Expansion

Effective clinical trial oversight is essential to achieving successful outcomes, particularly in the complex and fast-moving field of oncology. Identifying and resolving barriers quickly is critical—especially during Phase 1/2 expansion, where execution speed directly impacts value.

Canada offers a compelling environment for global oncology trials. A combination of world-class researchers, a diverse and accessible patient population, cost efficiency, and a reliable regulatory framework support high-quality, timely study delivery. These strengths make Canada an attractive location for patient enrollment and cohort expansion within global programs.

Geographically and demographically aligned with the United States, Canada is experiencing a significant increase in the number of cancer cases. Clinical trial participation rates have been reported to be approximately 14% in Canada, compared to 3–5% in the U.S., supporting strong enrollment potential.

Canada’s healthcare structure further enhances trial efficiency. Oncology patients are typically treated within specialized cancer centres and often remain within the same institution throughout their treatment journey. This continuity facilitates efficient patient identification and supports more predictable enrollment planning for expansion cohorts.

The regulatory and operational environment is also well suited to early-phase trials. A specialized Canadian CRO can tailor execution to the unique characteristics of Phase 1 oncology units. With established site relationships, local expertise, and experienced clinical teams, this approach enables sponsors to fully leverage Canada’s clinical trial ecosystem.

Recruitment Success

Canada is recognized for strong clinical trial enrollment performance, supported by engaged investigators and well-established research infrastructure. While recruitment outcomes vary by study, Canadian oncology centres consistently demonstrate high participation relative to global benchmarks.

Canada’s diverse population further strengthens its value for global trials. With immigrants representing a significant proportion of the population, and projections indicating that approximately one-third of the working-age population will belong to a visible minority group by 2036, the country offers access to a broad and representative patient base.

Canada’s integrated healthcare system and specialized oncology networks support efficient trial delivery. Patients are typically managed within dedicated cancer centres, enabling continuity of care and facilitating patient identification and enrollment planning for expansion cohorts.

Canada People of Color graph 300x249

Robust provincial and national data systems, such as cancer registries, provide valuable population-level insights that support feasibility assessments and site selection. While access to patient-level data is governed by strict privacy regulations, these systems contribute to informed and efficient recruitment strategies.

Universal Healthcare

Canada’s publicly funded healthcare system provides eligible residents with access to medically necessary hospital and physician services, reducing financial barriers to care. Healthcare delivery is managed at the provincial level, ensuring consistent coverage standards across the country.

This system supports broad access to care and contributes to well-defined patient pathways within oncology. With a large proportion of the population living in proximity to major healthcare centres, investigators benefit from access to concentrated patient populations within established treatment networks.

Recognized International Standards

Canada operates within a globally harmonized clinical research framework aligned with the International Council for Harmonisation (ICH) Good Clinical Practice (GCP) guidelines. Health Canada is an active ICH member and has incorporated these internationally recognized standards into its regulatory requirements.

As a result, clinical trials conducted in Canada adhere to the same ethical, scientific, and data integrity principles applied in major regulatory jurisdictions. Data generated in Canada is therefore well positioned for acceptance by international regulatory authorities—including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)—provided it meets established GCP and regulatory requirements.

Robust and Efficient Regulatory Environment

Canada offers a well-defined and efficient regulatory framework for clinical trial approvals, comparable in rigor to other major regions while enabling streamlined execution for sponsors. Health Canada’s Clinical Trial Application (CTA) process operates under a default 30-day review timeline, providing predictability and consistency for study start-up planning.

During the initial screening phase, requests for clarification require rapid sponsor response—typically within two calendar days—supporting an efficient and focused review process. This structured approach helps minimize delays and maintain momentum toward trial initiation. A partner with regulatory expertise will anticipate and address potential questions from Health Canada to avoid unnecessary delays and unforeseen costs for your oncology clinical trials P1/2 study expansion. An important key to a successful clinical trial application (CTA) submission.

Compared with other jurisdictions, Canada offers a clear and predictable pathway to study authorization. In the United States, while the FDA also operates on a 30-day review window for Investigational New Drug (IND) applications, trials may be delayed if a clinical hold is imposed. In the European Union, regulatory timelines can extend to 60 days or more depending on the review scope.

Canada’s consistent timelines and transparent process enable better coordination with Research Ethics Board submissions, allowing sponsors to streamline study start-up activities. Together, these factors contribute to faster and more predictable clinical trial initiation.

Top-Quality Data

Canada is widely recognized for generating high-quality clinical data in global studies, supported by experienced investigators, rigorous regulatory standards, and strong adherence to Good Clinical Practice.

This reputation is reinforced by a mature research ecosystem that includes leading academic institutions and specialized oncology centres. In early-phase oncology trials, Canadian sites consistently demonstrate strong protocol compliance, reliable data capture, and high levels of sponsor confidence in study outcomes.

Best Therapeutic Expertise for the Region

Enrollment success varies across studies, making the choice of CRO and site network a critical success factor for global oncology programs. In Canada, specialized CROs with deep local expertise are best positioned to leverage established disease networks and align the right investigators, sites, and patient populations with each study.

With nearly three decades of established relationships across leading cancer centres—including Phase 1 units—Scimega consistently enables faster activation and high-performing sites, many of which rank among top enrollers in global oncology studies.

Today, sponsors require more than execution—they need partners who can reliably deliver rapid First Patient In (FPI), efficient enrollment, and high-quality data. This depends on strong site relationships, accurate feasibility assessments, and streamlined contracting processes.

Scimega’s team brings extensive on-the-ground experience, including professionals with direct Phase 1 oncology site backgrounds. This expertise enables efficient communication, proactive problem-solving, and seamless coordination with investigators—critical to accelerating Phase 1/2 cohort expansion.

Site Selection & Accelerated Study Start-Up | Scimega. Combined with thoughtful site selection and deep therapeutic expertise, this approach supports consistent enrollment performance and high-quality study execution.

Partnering with Scimega provides a differentiated advantage—helping sponsors accelerate Phase 1/2 expansion while maximizing the performance of Canada’s oncology research environment.

Accelerate Your Next Phase

For drug developers navigating the transition from dose escalation to expansion, execution speed and partner expertise make a critical difference.

Canada offers the infrastructure. Scimega delivers the execution.

Together, this offers a clear path to accelerate your Phase 1/2 expansion—efficiently, reliably, and with confidence.

 

Canada-handshake_Favicon-512px Contributed by: Julie Martin, President & CEO